Simplifying Global Compliance
FDAnews Drug Daily Bulletin
FDA Agrees With AtheroNova’s Clinical Development Plan as Proposed
Dec. 15, 2011
AtheroNova has established a clear development plan, including Phase I and Phase II protocol outlines, based on the recently finalized minutes of its pre-IND meeting with the FDA for its AHRO-001, a compound for the treatment of atherosclerosis.
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing